MedKoo Cat#: 333161 Name: Retatrutide CAS#: 2381089-83-2 Chemical Formula: C221H342N46O68 Exact Mass: 4728.4718 Molecular Weight: 4731.42 Elemental Analysis: C, 56.10
News provided by Eli Lilly and Company Jul 23, 2026, 06:45 ET In TRIUMPH-2, adults with obesity or overweight and type 2 diabetes, a population with increased difficulties losing weight, lost up to an average of 49.6 lbs (20.8%) at 80 weeks In TRIUMPH-3, adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes, lost up to an average of 55.8 lbs (22.6%) at 80 weeks Lilly plans to submit a Biologics License Application (BLA) for retatrutide to FDA in Q1 2027 INDIANAPOLIS, July 23, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-2 and TRIUMPH-3, two pivotal Phase 3 trials evaluating retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist
Contraindications and Precautions Because Retatrutide is still under investigation, its full contraindication profile is not completely established
For certain treatments, such as brand-name GLP-1 pens, you may also have the option to pick your meds up locally at a pharmacy
Be aware of symptoms such as dry mouth, headache, or dizziness, all of which indicate that dehydration is contributing to the fatigue
